Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2017-01-15
2020-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Relevance of Nicardipine Induced Hypoxemia in the Intensive Care Unit
NCT05155202
Clinical Assessment of Arterial Dynamic Elastance in ICU Patients, Dependent on Inotropic or Vasopressor Drugs.
NCT03621618
Effects of Dihydropyridine Calcium Channel Inhibitors on Respiratory Gas Exchanges in the Intensive Care Unit: a Pharmacovigilance Study in VigiBase® and a Comparison With Urapidil
NCT05537194
The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure
NCT01971944
Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation
NCT00604331
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enteral nutrition
Enteral nutrition support
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Dependence of vasoactive drugs and/or mechanical circulatory support to at least 48 hours from Intensive Care Unit admission.
* Invasive mechanical ventilation time of at least 48 hours.
* Expected survival greater than 72 hours.
* ICU Stay greater than or equal to 72 hours.
Exclusion Criteria
* Refractory shock, defined as the progressive elevation of the dose of vasoactive drugs and / or markers of tissue hypoperfusion, or mean arterial pressure ≤ 60 mm Hg despite the therapeutic maneuvers.
* History of significant abdominal vascular disease (ischemic colitis, chronic mesenteric ischemia, aortic aneurysm abdominal, aortic dissection with involvement of mesenteric vessels, etc).
* Absolute contraindication for the onset of enteral nutrition (active gastrointestinal hemorrhage, intestinal obstruction, etc.) or patients with a non-functional gastrointestinal tract.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Universitario 12 de Octubre
OTHER
Hospital Severo Ochoa
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jose Luis Flordelis Lasierra, MD, PhD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jose Luis Flordelís Lasierra, MD, PhD
Role: STUDY_DIRECTOR
Hospital Universitario Severo Ochoa. Leganés. Madrid. Spain.
Juan Carlos Montejo González, MD, PhD
Role: STUDY_CHAIR
Hospital Universitario 12 de Octubre. Madrid. Spain
Luis Juan Terceros Almanza, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario 12 de Octubre. Madrid. Spain
Antonio Luis Blesa Malpica, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario Clínico San Carlos. Madrid. Spain
Emilio Renes Carreño, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario 12 de Octubre. Madrid. Spain
María Lourdes Cordero Lorenzana, MD
Role: PRINCIPAL_INVESTIGATOR
Complejo Hospitalario Universitario A Coruña. Galicia. Spain.
Juan Carlos López Delgado, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario de Bellvitge. Cataluña. Spain.
Paola Zárate Chug, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario Miguel Servet. Zaragoza. Spain.
Belén Vila García, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario Infanta Cristina. Parla. Madrid. Spain
Rosa María Gastaldo Simeón, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital de Manacor. Mallorca. Islas Baleares. Spain
Fátima Martínez Lozano Aranaga, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital General Universitario Reina Sofía. Murcia. Spain.
Carolina Lorencio Cárdenas, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario de Girona Josep Trueta. Gerona. Spain
Mónica Zamora Elson, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital de Barbastro. Huesca. Aragón. Spain.
Clara Vaquerizo Alonso, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario de Fuenlabrada. Madrid. Spain.
María Luisa Bordejé Laguna, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario Germans Trias i Pujol. Badalona. Barcelona. Cataluña. Spain.
Esther Portugal Rodríguez, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario Lucus Augusti. Lugo. Galicia. Spain.
Lluís Servià Goixart, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario Arnau de Villanova. Lérida. Cataluña. Spain.
Ana Martín Luengo, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario Río Ortega. Valladolid. Castilla y León. Spain
Carmen Martín Parra, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario del Tajo. Aranjuez. Madrid. Spain
Lidón Mateu Campos, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital General Universitario de Castellón. Comunidad Valenciana. Spain
Juan Francisco Fernández Ortega, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Regional Universitario de Málaga. Andalucía. Spain
Carlos Serón Arbeloa, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital de San Jorge. Huesca. Aragón. Spain
Elisabeth Navas Moya, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario Mútua Terrassa. Barcelona. Spain.
María del Mar Juan Díaz, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Clínico Universitario de Valencia. Comunidad Valenciana. Spain
Alexander Agrifolio Rotaeche, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario La Paz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Regional Universitario de Málaga
Málaga, Andalusia, Spain
Hospital de San Jorge
Huesca, Aragon, Spain
Hospital de Barbastro
Huesca, Aragon, Spain
Hospital Universitario Miguel Servet
Zaragoza, Aragon, Spain
Hospital de Manacor.
Palma de Mallorca, Balearic Islands, Spain
Hospital Universitario Río Hortega
Valladolid, Castille and León, Spain
Hospital Universitario de Bellvitge
Barcelona, Catalonia, Spain
Hospital Universitario Germans Trias i Pujol
Barcelona, Catalonia, Spain
Hospital Universitario de Girona Josep Trueta
Girona, Catalonia, Spain
Hospital Universitario Arnau de Villanova
Lleida, Catalonia, Spain
Hospital Universitario Mútua Terrassa
Terrassa, Catalonia, Spain
Complejo Hospitalario Universitario A Coruña
A Coruña, Galicia, Spain
Hospital Universitario Lucus Augusti
Lugo, Galicia, Spain
Hospital Universitario del Tajo
Aranjuez, Madrid, Spain
Hospital Universitario de Fuenlabrada
Fuenlabrada, Madrid, Spain
Hospital Universitario Severo Ochoa
Leganés, Madrid, Spain
Hospital Universitario Infanta Cristina
Parla, Madrid, Spain
Hospital General Universitario de Castellón
Castellon, Valencia, Spain
Hospital Clínico Universitario de Valencia
Valencia, Valencia, Spain
Hospital Universitario Clínico San Carlos
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Hospital General Universitario Reina Sofía
Murcia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HSeveroOchoa
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.